老虎證券

BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Reuters
2025/12/08
BUZZ-<a href="https://laohu8.com/S/RXRX">Recursion</a> climbs as experimental drug reduces polyp growth in rare disease trial

** Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket

** Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis

** In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy

** Co is looking to expand the study to a broader population of patients aged 18 years and above

** Up to last close, stock down 30.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10